10x Genomics, Inc. (TXG) — Analyst outlook / Analyst consensus target is. Based on 22 analyst ratings, the consensus is bullish — 10 Buy, 11 Hold, 1 Sell.
The consensus price target is $21.00 (low: $17.00, high: $25.00), representing a downside of 15.3% from the current price $24.80.
Analysts estimate Earnings Per Share (EPS) of $-1.41 and revenue of $0.61B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.52 vs est $-1.41 (missed -7.6%). 2025: actual $-0.35 vs est $-0.43 (beat +17.9%). Analyst accuracy: 86%.
TXG Stock — 12-Month Price Forecast
$21.00
▼ -15.32% Downside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for 10x Genomics, Inc., the average price target is $21.00, with a high forecast of $25.00, and a low forecast of $17.00.
The average price target represents a -15.32% change from the last price of $24.80.
Highest Price Target
$25.00
Average Price Target
$21.00
Lowest Price Target
$17.00
TXG Analyst Ratings
Hold
Based on 22 analysts giving stock ratings to 10x Genomics, Inc. in the past 3 months
EPS Estimates — TXG
86%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.52
vs Est –$1.41
▼ 7.1% off
2025
Actual –$0.35
vs Est –$0.43
▲ 21.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TXG
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.611B
vs Est $0.605B
▲ 0.9% off
2025
Actual $0.643B
vs Est $0.636B
▲ 1.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
